PMID

Data

Article Title

Organization

(18)F-AmBF3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging.

Bc Cancer Agency

Studies toward the development of new silicon-containing building blocks for the direct (18)F-labeling of peptides.

Institute of Technology (Eth) Zurich

Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.

The Ohio State University

Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate.

Universit£

PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.

Cambridge University Forvie Site

 

PD 165929 the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist

TBA

Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

TBA

Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.

Merck Research Laboratories

Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.

Merck Research Laboratories

Discovery and optimization of a novel Neuromedin B receptor antagonist.

Amgen

Structural assessment and biological evaluation of two N3S bombesin derivatives.

Institutes of Radioisotopes-Radiodiagnostic Products and Biology

Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead.

Glaxosmithkline

Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.

National Center For Scientific Research Demokritos

Design of selective peptidomimetic agonists for the human orphan receptor BRS-3.

Technische UniversitäT MüNchen

Potent gastrin-releasing peptide (GRP) antagonists derived from GRP (19-27) with a C-terminal DPro psi [CH2NH]Phe-NH2 and N-terminal aromatic residues.

Burroughs Wellcome

Gastrin releasing peptide antagonists with improved potency and stability.

Merck Sharp & Dohme Research Laboratories

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Sanofi-Synthelabo Recherche

Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).

National Institute of Diabetes and Digestive and Kidney Diseases